Challenge of Surrogate Endpoints

被引：3
|
作者：
Furgerson, James L. [1 ]
Hannah, William N., Jr. [1 ]
Thompson, Jennifer C. [1 ]
机构：
[1] Brooke Army Med Ctr, MCHE MED Cardiol Serv, Dept Med, Ft Sam Houston, TX 78234 USA
来源：
SOUTHERN MEDICAL JOURNAL | 2012年 / 105卷 / 03期
关键词：
biomarkers; clinical endpoint; intermediate endpoint; surrogate endpoint; DENSITY-LIPOPROTEIN CHOLESTEROL; HUMAN ATHEROSCLEROTIC LESIONS; ESTROGEN PLUS PROGESTIN; CORONARY-HEART-DISEASE; RISK-FACTOR; FOLIC-ACID; PLASMA HOMOCYSTEINE; CARDIOVASCULAR-DISEASE; SECONDARY PREVENTION; VASCULAR-DISEASE;
D O I：
10.1097/SMJ.0b013e318249891e
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Surrogate endpoints are biomarkers that are intended to substitute for clinical endpoints. They have been used to find novel therapeutic targets, improve the statistical power and shorten the duration of clinical trials, and control the cost of conducting research studies. The more generalized use of surrogate endpoints in clinical decision making can be hazardous and should be undertaken with great caution. This article reviews prior work with surrogate endpoints and highlights caveats and lessons learned from studies using surrogate endpoints.
引用
收藏
页码：156 / 160
页数：5
相关论文
共 50 条
  • [1] Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease
    Rasnake, Crystal M.
    Trumbo, Paula R.
    Heinonen, Therese M.
    NUTRITION REVIEWS, 2008, 66 (02) : 76 - 81
  • [2] Overview of biomarkers and surrogate endpoints in drug development
    Wagner, JA
    DISEASE MARKERS, 2002, 18 (02) : 41 - 46
  • [3] Principles of use of surrogate markers and endpoints
    Kluft, C
    MATURITAS, 2004, 47 (04) : 293 - 298
  • [4] The perils of surrogate endpoints
    Weintraub, William S.
    Luescher, Thomas F.
    Pocock, Stuart
    EUROPEAN HEART JOURNAL, 2015, 36 (33) : 2212 - 2218
  • [5] A new proportion measure of the treatment effect captured by candidate surrogate endpoints
    Kobayashi, Fumiaki
    Kuroki, Manabu
    STATISTICS IN MEDICINE, 2014, 33 (19) : 3338 - 3353
  • [6] Ultrasound and radiology surrogate endpoints in pharmacological studies
    Agewall, S.
    deGroot, E.
    Marcos-Alberca, P.
    Zamorano, J. L.
    Barrero, A. A.
    Badano, L. P.
    Perrone-Filardi, P.
    ATHEROSCLEROSIS, 2012, 224 (01) : 12 - 24
  • [7] Information recovery in a study with surrogate endpoints
    Chen, SX
    Leung, DHY
    Qin, J
    JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2003, 98 (464) : 1052 - 1062
  • [8] Validation of surrogate endpoints in digestive oncology
    Methy, N.
    Bedenne, L.
    Bonnetain, F.
    BULLETIN DU CANCER, 2009, 96 (05) : 591 - 595
  • [9] Quantification of the prentice criteria for surrogate endpoints
    O'Quigley, J
    Flandre, P
    BIOMETRICS, 2006, 62 (01) : 297 - 300
  • [10] Biomarkers and surrogate endpoints in kidney disease
    Hartung, Erum A.
    PEDIATRIC NEPHROLOGY, 2016, 31 (03) : 381 - 391
12345